ClinicalTrials.gg
RecruitingNCT07940920LIVE-CLLUpdated Nov 17, 2026

A Personalised Anti-fatigue Program for Community-dwelling People With Chronic Lymphocytic Leukaemia

An interventional study of LIVE-CLL personalised home-based physical activity program in Chronic Lymphocytic Leukemia and Fatigue Syndrome, Chronic, sponsored by University of Surrey. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Surrey · Not applicable, Interventional, and Supportive care

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United Kingdom — 25 open to participants now, 46 under way, 20 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United Kingdom.

Planned enrollment
109th of 130
60 · median 200
Started
2026
with 5 others
No phase
3 of 139
1 open now
Primary completion
2027-11
later than 21 of 45 live
Registered
139th of 139
by date

Among the 139 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United Kingdom, this one is the 109th largest by planned enrollment of the 130 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 with no phase, reaches primary completion later than 21 of the 45 other live ones, and was the 139th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

25 of the 139 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United Kingdom are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this pilot study is to learn if a personalised, home-based online physical activity program (LIVE-CLL) is feasible for adults with chronic lymphocytic leukaemia (CLL) who experience fatigue. It will also learn if the program improves fatigue, symptoms and quality of life. The main questions it aims to answer are:

Can people with CLL be recruited to the program, attend their prescribed sessions, follow the prescribed exercise intensities, and stay in the study? Do fatigue, symptoms and quality of life change after 12 weeks of the program?

All participants will receive the LIVE-CLL program alongside their usual care. Researchers will compare measurements taken before and after the program.

Participants will:

Complete online fitness assessments and questionnaires by video call before and after the program Follow a personalised 12-week aerobic and strength program at home, 3 to 5 sessions per week, delivered through an exercise app Complete a short check-in form before each session and a wellbeing form each week, so the program can be adjusted

Read the detailed description

Background and rationale

Compared with people with solid tumours, people with haematological malignancies, including CLL, have greater physical deconditioning, worse quality of life and a heavier symptom burden, especially fatigue. In CLL, fatigue is common in treatment-naïve patients, more severe in treated patients, and an independent predictor of poor quality of life. Preliminary survey data collected with the CLL Support Association (approximately 1,000 respondents) show that fatigue prevalence and severity increased between 2022 and 2024, and that patients are rarely referred to services that can address it.

Cancer-related fatigue has many causes. In treated CLL, the BTK inhibitors (e.g., ibrutinib) and BCL2 inhibitors (e.g., venetoclax) have off-target effects on skeletal and cardiac muscle, which may contribute to fatigue and to the higher risk of cardiac events. Fatigue and frailty are also more common in treatment-naïve CLL than in the general population. The investigators' published metabolic biomarker data suggest that CLL cells may use lipid-based fuels that skeletal and cardiac muscle depend on. Together, these mechanisms suggest that fatigue in CLL may differ from fatigue in solid tumours. CLL patients may therefore benefit from a disease-specific, symptom-targeted approach, given at diagnosis (prehabilitation) and when treatment starts (rehabilitation), rather than generic exercise oncology programs.

Patient and public involvement

The intervention design is based on a 2022 patient focus group and online survey of people with CLL. These covered exercise motivations and barriers, intervention preferences, the role of diet and nutrition, and research priorities. It was also refined using feedback from 60 participants who completed a previous 6-month exercise trial run by the investigators. That feedback showed demand for lifestyle approaches that target symptoms such as fatigue and can be delivered in the community.

Study design

This is a prospective, single-arm, pre-test/post-test pilot feasibility study. Formal power calculations were not performed. The target sample of 30 per subgroup (treatment-naïve and on-treatment) follows standard recommendations for pilot studies that aim to generate estimates for powering a definitive trial. Participants are recruited when they are unlikely to change treatment pathway during the study (e.g., moving from watch-and-wait to treatment, or finishing fixed-duration venetoclax). Recruitment is expected to run at 6-10 participants per 4-week period over a 37-week window.

Pre-participation screening

The FACIT-Fatigue is completed online. Eligible participants then have a virtual screening session on MS Teams, which covers medical history, cancer history, emergency contacts and where they will exercise. Exercise readiness is assessed with the PAR-Q+. Participants flagged for further evaluation complete the ePARmed-X+ and need medical clearance from their healthcare provider. Any intensity restrictions the provider recommends are built into the exercise prescription. A Clinical Exercise Physiologist then writes a medical summary form for use during assessments and program delivery.

Remote assessment procedures

Assessments are done by video call with two trained exercise professionals: a primary assessor and a secondary assessor, who records results and supports safety procedures. Before testing, the team checks the participant's home environment and equipment and chooses a suitable test battery. Whether each assessment can be completed remotely is itself a feasibility measure, and not being able to complete a test does not exclude a participant. Physical performance is assessed with standardised online fitness assessment protocols for exercise oncology (Daun et al., 2024). Resting heart rate and blood pressure are measured with the participant's own devices or by assessor-guided pulse palpation. A wrist-worn activity/heart-rate monitor may be posted to participants. Anthropometrics are self-reported using standardised instructions, or taken from a recent clinical record. Patient-reported measures are collected through Qualtrics. Dietary intake is assessed with a 7-day food diary and the short-form food frequency questionnaire. Comorbidity burden is assessed with the CLL Comorbidity Index (CLL-CI).

Intervention

Exercise prescription follows the Sasso et al. (2015) framework for exercise-oncology research and ACSM exercise prescription guidelines, in line with UK Chief Medical Officers' physical activity guidelines. A Clinical Exercise Physiologist writes each program. Programs combine aerobic and resistance exercise to target the limitations found at baseline. Intensity ranges from low (e.g., walking) to moderate (e.g., jogging), based on PAR-Q+ safety zones, and is regulated with ratings of perceived exertion (Borg 6-20 or CR-10). Resistance is adapted to the equipment the participant has, including household items. Programs are delivered through Physitrack, a web and mobile exercise prescription platform used across more than 60 NHS trusts. Participants log in with study-issued IDs, so no personal data is held on the platform. Optional live online group classes are run by a Clinical Exercise Physiologist with a second team member present.

Programs are adjusted continuously based on participant reports. Before each session, participants complete a readiness form covering new injuries, illness and fatigue on a 0-10 scale. If fatigue is above 7/10, or new symptoms are reported, an alternative low-intensity session is offered and the participant is advised to contact the team. A more detailed weekly physical and mental wellbeing form guides progression or regression, and the team arranges a video or phone call if there are wellbeing concerns. An onboarding call introduces the platform before the intervention starts.

Safety monitoring

Self-directed sessions are not monitored in real time. Team support is available 09:00-17:00, Monday to Friday. Out-of-hours risk is managed by:

Giving explicit emergency guidance (call 999; use NHS 111, the GP or the haematology team for urgent non-emergency concerns) Asking participants to tell a contact before each session and keep a phone nearby Encouraging sessions during team hours, especially early in the program Requiring a friend or family member to be present, and team supervision instead of self-directed sessions, for participants classed as weak or frail at baseline

During live sessions, one team member stays with the participant while the second calls emergency services and the emergency contacts.

Exercise-related adverse events are collected from the first exercise test to the last. They are graded with CTCAE v5.0 (or mild to fatal where no CTCAE grading exists) and recorded as related or unrelated to study procedures. Expected minor effects (fatigue, muscle soreness, joint or lower back pain, leg cramps) are not recorded as adverse events. Serious adverse events are reported to the University Ethics Committee within 24 hours. The exercise physiologist is a Level 4 Cancer Rehabilitation Specialist.

Statistical analysis

Participant characteristics will be summarised as mean ± SD or median (IQR), depending on distribution. Feasibility will be judged against pre-set thresholds for recruitment, adherence, compliance and retention. Pre-to-post changes in continuous outcomes will be analysed with linear mixed models, using non-parametric alternatives if data are not normally distributed. Categorical outcomes will be analysed with Pearson chi-square tests. Statistical significance is set at p ≤ 0.05, and trends are noted at p ≤ 0.10. Effect estimates will be used to inform the sample size for a future controlled trial.

Ethics, data management and funding

The study is reviewed by the University of Surrey Ethics Committee. Participants are not recruited through the NHS, so NHS REC review is not required. Data are collected through Qualtrics, moved to secure University servers within 2 weeks, and pseudonymised. Identifiable data are stored separately with restricted access. Records are kept for at least 10 years. The study is funded by Blood Cancer UK.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Fatigue Syndrome, Chronic

Keywords

  • Chronic lymphocytic leukaemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Cancer-related fatigue
  • Fatigue
  • Exercise
  • Physical activity
  • Home-based exercise
  • Digital health intervention
  • Quality of life
  • Exercise oncology
  • Haematological malignancy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Confirmed diagnosis of chronic lymphocytic leukaemia (CLL), including small lymphocytic lymphoma (SLL), according to International Workshop on CLL (iwCLL) guidelines
  • fatigue, defined as a FACIT-Fatigue total score of less than 34
  • Either treatment-naïve or currently receiving CLL treatment, and not expected to change treatment pathway during the 12-week study (e.g., starting treatment or completing fixed-duration therapy)
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

No access to the digital platforms used to assess participants and deliver the program (e.g., internet-connected device for video calls and the exercise app)

  • Absolute to physical activity, including self-reported:
  • Acute cardiac event within the past 6 months
  • Unstable angina
  • Uncontrolled dysrhythmias causing symptoms or haemodynamic compromise
  • Symptomatic aortic stenosis
  • Uncontrolled symptomatic heart failure
  • Acute pulmonary embolus
  • Acute myocarditis or pericarditis
  • Suspected or known dissecting aneurysm
  • Acute systemic infection
  • Participants flagged by the PAR-Q+ / ePARmed-X+ as requiring medical clearance, who do not receive clearance to exercise from their healthcare provider
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    LIVE-CLL Program

    Adults with CLL and fatigue (FACIT-Fatigue \<34), both treatment-naïve and on treatment, receive a personalised 12-week home-based online physical activity program alongside usual care.

    Behavioral: LIVE-CLL personalised home-based physical activity program

Interventions

  • BehavioralLIVE-CLL personalised home-based physical activity program

    A 12-week, semi-supervised, home-based aerobic and resistance exercise program prescribed by a Clinical Exercise Physiologist using ACSM guidelines. It targets the physical limitations found at baseline assessment. Sessions are 3 to 5 per week, at low to moderate intensity regulated by rating of perceived exertion (Borg scale). They are delivered through the Physitrack app, with optional live online group classes. A readiness check before each session and a weekly wellbeing form are used to progress, regress or replace sessions.

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    Number of participants enrolled per 4-week period, and total enrolled against the target of 60. The target rate is 6 to 10 participants per 4 weeks.

    Time frame: Over the 37-week recruitment period

  2. Adherence to prescribed sessions

    Percentage of prescribed weekly exercise sessions completed, recorded on the Physitrack platform. Feasibility is met if adherence is above 85%.

    Time frame: Baseline to week 12

  3. Compliance with prescribed exercise intensity and duration

    Percentage of participants who complete sessions at the prescribed intensity (rating of perceived exertion) and duration, based on session logs. Feasibility is met if more than 80% comply.

    Time frame: Baseline to week 12

  4. Retention

    Percentage of enrolled participants who drop out before the post-intervention assessment. Feasibility is met if fewer than 15% drop out.

    Time frame: Baseline to week 12

Secondary outcomes

  1. Completion of remote assessments

    Proportion of planned online physical assessments that are completed successfully.

    Time frame: Baseline and week 12 (post-intervention)

  2. FACIT-Fatigue

    Functional Assessment of Chronic Illness Therapy - Fatigue scale. Range 0-52; higher scores mean less fatigue.

    Time frame: Baseline and week 12 (post-intervention)

  3. Fatigue Assessment Scale (FAS)

    Range 10-50; higher scores mean more fatigue.

    Time frame: Baseline and week 12 (post-intervention)

  4. Fatigue Severity Scale (FSS)

    Mean item score, range 1-7; higher scores mean more severe fatigue.

    Time frame: Baseline and week 12 (post-intervention)

  5. Health-related quality of life (EORTC QLQ-C30)

    Global health status, functional scales and symptom scales, each scored 0-100. Higher functional and global scores mean better function. Higher symptom scores mean more symptoms.

    Time frame: Baseline and week 12 (post-intervention)

  6. CLL-specific quality of life (EORTC QLQ-CLL17)

    Symptom burden, physical condition/fatigue, and worries/fears scales, each scored 0-100. Higher scores mean more problems.

    Time frame: Baseline and week 12 (post-intervention)

  7. Lymphoma-specific quality of life (FACT-Lym)

    Total score 0-168; higher scores mean better quality of life.

    Time frame: Baseline and week 12 (post-intervention)

  8. Anxiety and depression (HADS)

    Hospital Anxiety and Depression Scale. Anxiety and depression subscales, each 0-21; higher scores mean more symptoms.

    Time frame: Baseline and week 12 (post-intervention)

  9. Cognitive function (FACT-Cog)

    Perceived cognitive impairment and related subscales; higher scores mean better cognitive function.

    Time frame: Baseline and week 12 (post-intervention)

  10. Sleep quality (Pittsburgh Sleep Quality Index)

    Global score 0-21; higher scores mean worse sleep quality.

    Time frame: Baseline and week 12 (post-intervention)

  11. Geriatric vulnerability (G8)

    Range 0-17; a score of 14 or below indicates geriatric vulnerability.

    Time frame: Baseline and week 12 (post-intervention)

  12. Leisure-time physical activity (Godin Leisure-Time Exercise Questionnaire)

    Leisure Score Index; higher scores mean more activity.

    Time frame: Baseline and week 12 (post-intervention)

  13. Physical activity level (Stanford Brief Activity Survey)

    Categorical activity level, from inactive to very active.

    Time frame: Baseline and week 12 (post-intervention)

  14. Lower-body strength (30-second sit-to-stand test)

    Number of repetitions in 30 seconds.

    Time frame: Baseline and week 12 (post-intervention)

  15. Aerobic endurance (2-minute step test)

    Number of steps in 2 minutes.

    Time frame: Baseline and week 12 (post-intervention)

  16. Balance (single-leg stance test)

    Time in seconds.

    Time frame: Baseline and week 12 (post-intervention)

  17. Lower-body flexibility (chair sit-and-reach test)

    Distance in centimetres.

    Time frame: Baseline and week 12 (post-intervention)

  18. Shoulder flexion range of motion

    Degrees

    Time frame: Baseline and week 12 (post-intervention)

  19. Resting heart rate and blood pressure

    Beats per minute; mmHg.

    Time frame: Baseline and week 12 (post-intervention)

  20. Body mass index

    kg/m², from self-reported height and weight.

    Time frame: Baseline and week 12 (post-intervention)

  21. Dietary quality

    Dietary quality score from the short-form food frequency questionnaire (SFFFQ), plus energy and macronutrient intake from a 7-day food diary.

    Time frame: Baseline and week 12 (post-intervention)

  22. Exercise-related adverse events

    Number of participants with adverse events related to exercise testing or training, graded with CTCAE v5.0.

    Time frame: From first exercise test to post-intervention assessment (12 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov AV. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clin Cancer Res. 2021 Sep 1;27(17):4814-4824. doi: 10.1158/1078-0432.CCR-20-3993. Epub 2021 Jun 24. PubMed 34168050 ↗
  • Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle. 2015 Jun;6(2):115-24. doi: 10.1002/jcsm.12042. Epub 2015 May 11. PubMed 26136187 ↗
  • Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. PubMed 29540348 ↗
  • Eek D, Ivanescu C, Corredoira L, Meyers O, Cella D. Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia. J Patient Rep Outcomes. 2021 Mar 11;5(1):27. doi: 10.1186/s41687-021-00294-1. PubMed 33709202 ↗
  • Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007 Oct;139(2):255-64. doi: 10.1111/j.1365-2141.2007.06791.x. PubMed 17897301 ↗
  • Artese AL, Sitlinger A, MacDonald G, Deal MA, Hanson ED, Pieper CF, Weinberg JB, Brander DM, Bartlett DB. Effects of high-intensity interval training on health-related quality of life in chronic lymphocytic leukemia: A pilot study. J Geriatr Oncol. 2023 Jan;14(1):101373. doi: 10.1016/j.jgo.2022.09.002. Epub 2022 Sep 9. PubMed 36096873 ↗
  • MacDonald G, Sitlinger A, Deal MA, Hanson ED, Ferraro S, Pieper CF, Weinberg JB, Brander DM, Bartlett DB. A pilot study of high-intensity interval training in older adults with treatment naive chronic lymphocytic leukemia. Sci Rep. 2021 Nov 30;11(1):23137. doi: 10.1038/s41598-021-02352-6. PubMed 34848750 ↗
  • Sitlinger A, Deal MA, Garcia E, Connelly M, Thompson D, Stewart T, Macdonald G, Hanson ED, Neely M, Neely B, Artese A, Weinberg JB, Brander D, Bartlett DB. Associations of clinical and circulating metabolic biomarkers with low physical fitness and function in adults with chronic lymphocytic leukemia. Front Oncol. 2022 Aug 3;12:933619. doi: 10.3389/fonc.2022.933619. eCollection 2022. PubMed 35992862 ↗
  • Miles EE, Nicol JL, Fowler H, Roberts A, Hulton AT, Jeary C, Walewska R, Iyengar S, Hanson ED; CLL Support Association; Sitlinger A, Bartlett DB. Physical Activity, Symptoms, Quality of Life and Exercise Program Preferences in People With Chronic Lymphocytic Leukaemia. EJHaem. 2025 Jul 10;6(4):e70100. doi: 10.1002/jha2.70100. eCollection 2025 Aug. PubMed 40642445 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymised individual participant data underlying the published results (feasibility metrics, questionnaire scores, physical performance and dietary data) will be shared for participants who consented to data sharing. No directly identifiable information will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will be available after publication of the primary results and for at least 10 years, in line with the study's data retention policy.

Access criteria: Data will be made available to researchers who submit a methodologically sound proposal, on request to the Principal Investigator (d.bartlett@surrey.ac.uk). Access will require a data sharing agreement with the University of Surrey. Data will be shared only for participants who consented to data sharing.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.

Of 37 non-industry interventional studies with no phase under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 134. This study's planned 11 months is below that.

Counting every sponsor, half of 39 studies reached it within 42 months; a quarter within 27 and three quarters within 134.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940920
Lead sponsor
University of Surrey
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

David B Bartlett, PhD
Contact
d.bartlett@surrey.ac.uk
+44
Ellie Miles, PhD
Contact
e.e.miles@surrey.ac.uk
David Bartlett, PhD
principal investigator · University of Surrey

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion